Sacroiliitis Treatment Market Report 2026

The sacroiliitis treatment market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing prevalence of inflammatory spinal disorders, wider use of diagnostic imaging, improved understanding of sacroiliac joint pathology, expansion of pain management clinics, availability of advanced pharmacological therapies.

The sacroiliitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing adoption of biologic drugs, rising demand for minimally invasive pain treatments, expansion of outpatient orthopedic procedures, growing integration of digital diagnostics, increasing focus on long-term mobility restoration. Major trends in the forecast period include increasing use of image-guided diagnostic techniques, rising adoption of minimally invasive si joint fusion, growing preference for biologic and targeted therapies, expansion of radiofrequency-based pain management, enhanced focus on personalized treatment approaches.

The increasing incidence of joint disorders is expected to drive the growth of the sacroiliitis treatment market going forward. Joint disorders are conditions that affect the joints, causing pain, inflammation, stiffness, and reduced mobility due to factors such as injury, aging, autoimmune diseases, or infections. The rise in joint disorder cases is primarily attributed to aging populations, as natural wear and tear on the joints leads to a higher prevalence of conditions like osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment supports joint disorder management by reducing inflammation and pain in the sacroiliac joints, improving mobility and overall joint function, thereby alleviating symptoms and preventing further joint damage. For instance, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, osteoarthritis (OA) is projected to affect 2.35 million Australians in 2025, accounting for 57% of the total arthritis population, making it the most common form of arthritis in the country. By 2040, the number of Australians with OA is expected to increase to 3.11 million, representing a 32% rise from 2025, corresponding to an additional 762,515 people living with OA. Therefore, the increasing incidence of joint disorders is fueling the growth of the sacroiliitis treatment market.

Major companies operating in the sacroiliitis treatment market are focusing on securing regulatory approvals to accelerate the launch of innovative therapies, ensure market access, and enhance their competitive position. Regulatory approvals refer to the formal authorization granted by government health agencies confirming that a medical treatment is safe and effective for public use. For instance, in December 2023, Spinal Simplicity, a US-based medical equipment manufacturer, received FDA 510(k) clearance for its Liberty-SI Lateral Implant System, a minimally invasive, transfixing device for sacroiliac joint fusion in patients with sacroiliac disruptions or degenerative sacroiliitis. The system uses a lateral approach, inserting one or two titanium implants through the ilium across the SI joint into the sacrum to provide stabilization and fusion. The implants feature a central threaded body with deployable wings and compressive elements, come in multiple sizes, and are coated with hydroxyapatite to improve integration. The procedure is designed to be safer and less invasive, potentially reducing anesthesia time and improving patient outcomes.

In November 2023, Nevro Corp., a US-based medical device company specializing in innovative pain management solutions, acquired Vyrsa Technologies for an undisclosed amount. Through this acquisition, Nevro Corp. aims to strengthen its portfolio in minimally invasive treatments and accelerate the development and adoption of Vyrsa’s advanced spinal technologies by leveraging its commercial infrastructure and clinical expertise. Vyrsa Technologies is a US-based medical device company offering minimally invasive sacroiliitis treatment solutions, with a focus on sacroiliac joint fusion.

Major companies operating in the sacroiliitis treatment market are Pfizer Inc, Johnson And Johnson, AbbVie Inc, Novartis AG, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Amgen Inc, Biogen Inc, Sandoz Group AG, UCB SA, Hikma Pharmaceuticals PLC, Samsung Bioepis Co Ltd, Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co Ltd, Torrent Pharmaceuticals Limited, Globus Medical, Orthofix Medical Inc, Coherus BioSciences Inc, SI BONE Inc, Medtronic plc.

North America was the largest region in the sacroiliitis treatment market in2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sacroiliitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sacroiliitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the sacroiliitis treatment market by raising costs of imported biologic drugs, imaging equipment, radiofrequency ablation devices, and minimally invasive surgical tools. Specialty clinics and hospitals in North America and Europe are most impacted due to dependence on imported medical technologies, while Asia-Pacific faces higher costs for advanced diagnostics and biologics. These tariffs are increasing treatment costs and influencing therapy selection. However, they are also promoting domestic production of medical devices, localized pharmaceutical manufacturing, and investment in cost-optimized treatment solutions.

The sacroiliitis treatment market research report is one of a series of new reports that provides sacroiliitis treatment market statistics, including sacroiliitis treatment industry global market size, regional shares, competitors with a sacroiliitis treatment market share, detailed sacroiliitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sacroiliitis treatment industry. This sacroiliitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sacroiliitis treatment refers to the medical care used to manage inflammation of one or both sacroiliac joints, located where the lower spine meets the pelvis. This condition can cause pain in the lower back, buttocks, or legs and may be associated with inflammatory conditions such as ankylosing spondylitis. The primary goal of treatment is to reduce inflammation, relieve pain, and restore mobility.

The primary types of sacroiliitis treatment include medications, joint injections, joint fusion, radiofrequency denervation, and electrical stimulation. Medications primarily consist of nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics, which help reduce pain and inflammation in the sacroiliac joint. Diagnostic methods include imaging tests, physical examinations, laboratory tests, and others, with administration routes such as oral, injectable, or topical. Treatments serve a wide range of end users, including hospitals, specialty clinics, ambulatory surgical centers, and homecare settings.

The sacroiliitis treatment market includes revenues earned by entities by providing services, such as anti-inflammatory medications, pharmacological treatment, physical therapy, interventional pain management, surgical services, and chiropractic and osteopathic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.